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Abstract
Aims We aim to study the feasibility and clinical value of pulmonary artery pressure monitoring with the CardioMEMS™
device in order to optimize and guide treatment in patients with a HeartMate 3 left ventricular assist device (LVAD).
Methods and results In this single-centre, prospective pilot study, we will include 10 consecutive patients with New York
Heart Association Class IIIb or IV with Interagency Registry for Mechanically Assisted Circulatory Support Classes 2–5 scheduled
for implantation of a HeartMate 3 LVAD. Prior to LVAD implantation, patients will receive a CardioMEMS sensor, for daily
pulmonary pressure readings. The haemodynamic information provided by the CardioMEMS will be used to improve
haemodynamic status prior to LVAD surgery and optimize the timing of LVAD implantation. Post-LVAD implantation, the
haemodynamic changes will be assessed for additive value in detecting potential complications in an earlier stage (bleeding
and tamponade). During the outpatient clinic phase, we will assess whether the haemodynamic feedback can optimize pump
settings, detect potential complications, and further tailor the clinical management of these patients.
Conclusions The HEMO-VAD study is the ﬁrst prospective pilot study to explore the safety and feasibility of using
CardioMEMS for optimization of LVAD therapy with additional (remote) haemodynamic information.
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Introduction
As the prevalence and incidence of heart failure (HF) keeps
increasing, more and more patients develop end-stage HF
despite improved medical management.1–3 About 10–15%
of the HF patients develop advanced HF every 3 years and
become refractory to drug therapy, leaving heart transplanta-
tion or haemodynamic support by left ventricular assist
device (LVAD) implantation as the only therapy option.1
Experience with LVADs is rapidly growing worldwide;
however, mortality and morbidity of this advanced therapy
remains high. LVAD therapy is life-saving but remains an
intensive complex treatment with high rehospitalization rates
and outpatient clinic contacts.4 Recently, novel LVAD designs
have improved post-operative outcomes with amarked reduc-
tion in pump thrombosis and cerebrovascular accidents,5 but
bleeding, driveline infections, and long-term right ventricle
(RV) failure continue to impair the long-term efﬁcacy of this in-
tervention.6–8 Patients with long-term LVAD therapy remain
particularly vulnerable for RV failure, with up to 20–40% of
the patients developing early RV failure5,9,10 and 15% late RV
failure.11 Severe RV dysfunction remains the leading cause of
death in the ﬁrst month after LVAD implantation.12,13 There
is a growing clinical demand for physicians to have better ways
to predict response to treatment as well as tailor clinical man-
agement in these patients. Currently, the pump controller only
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reﬂects a ﬁxed number of rotations per minute (rpm) and
notiﬁcations of a calculated pump ﬂow and pulse index of
the device itself but no actual haemodynamic feedback.
The CardioMEMS™ pulmonary artery (PA) sensor allows
frequent remote monitoring of haemodynamic information,
with proven effectiveness in reducing HF hospitalizations by
maintaining normal pulmonary artery pressure (PAP) as
surrogate markers of ﬁlling pressures (which rise in
eminent decompensation) in chronic HF patients.14,15 An
innovation would be to combine two state-of-the-art strat-
egies such as LVAD therapy and guidance by PA monitoring
in order to improve the outcome in this complex patient
category and reduce the high burden of complications by
early detection of pressure shifts. New insights will be
provided by such haemodynamic feedback in order to
tailor therapy in this patient group as well as to learn
more on RV dynamics and pulmonary hypertension during
long-term treatment with daily haemodynamic data. In
order to study the feasibility and clinical value of the
hybrid construction of CardioMEMS and HeartMate 3
(HM-3), we present the pilot study design to address this
hypothesis in LVAD patients.
Study design
This is an investigator-initiated, single-centre, prospective
pilot study enrolling 10 consecutive patients who undergo
a scheduled semi-elective or elective implantation of an
HM-3 LVAD. The decision for LVAD therapy will be
established by heart team consensus. Before LVAD implan-
tation, all patients will receive a Swan–Ganz right heart
catheterization, and a CardioMEMS PA sensor will be
implanted to measure PAP. This study has been approved
by the ethics committee (MEC no. 2017-342), and the study
will be conducted according to the Helsinki declaration,
with all patients providing informed consent prior to
participation. The study is registered at clinicaltrails.gov
under NTR 2017-6804.
Study population
The HEMO-VAD pilot study involves 10 patients with New
York Heart Association functional Class IIIb or IV with
Interagency Registry for Mechanically Assisted Circulatory
Support (INTERMACS) Classes 2–5, who undergo a scheduled
implantation of an HM-3 LVAD at the Erasmus MC
Thoraxcentre, Rotterdam, The Netherlands. Inclusion criteria
are presented in Table 1, and exclusion criteria are presented
in Table 2.
Objectives and endpoints
The objectives of this study are as follows:
• to investigate the feasibility and safety of using haemody-
namic guidance by the CardioMEMS PA sensor in LVAD
HM-3 patients,
• to investigate the information provided by haemodynamic
data of CardioMEMS PA sensor in relation to incident
LVAD complications prospectively, and
• to study haemodynamics (PAP) preoperatively and
post-operatively of LVAD surgery.
The proposed impact and goals of haemodynamic
guidance in LVAD patients are further shown in Table 3.
All study endpoints are shown in Table 4.
Table 1 Inclusion criteria
- Age ≥ 18 years
- LVEF < 25%
- NYHA Class IIIb or NYHA Class IV with INTERMACS Classes 2–5
- Scheduled for LVAD implantation within 1 month after heart
team consensus
- Life expectancy > 1 year
- Body surface area ≥ 1.2 m2 and chest circumference, at the axillary
level, of less than 65 in. if BMI > 35 kg/m2
- Signed informed consent form
BMI, body mass index; LVAD, left ventricular assist device; LVEF, left
ventricular ejection fraction; INTERMACS, Interagency Registry for
Mechanically Assisted Circulatory Support; NYHA, New York Heart
Association.
Table 2 Exclusion criteria
- No signed informed consent form
- INTERMACS 1 emergency LVAD implantations
- Patients with a known coagulation disorder or hypersensitivity to
aspirin
- Intolerance to anticoagulant or antiplatelet therapies
- Patients with contraindications for the PAP sensor device, which
will include active infection, a history of deep vein thrombosis or
recurrent pulmonary embolism, mechanic right heart valve, or
unable to tolerate Swan–Ganz
- History of pulmonary embolism within 30 days prior to enrolment
or history of recurrent (>1 episode) pulmonary embolism and/or
deep vein thrombosis
- History of stroke within 90 days prior to enrolment or a history of
cerebrovascular disease with signiﬁcant (>80%) uncorrected
carotid stenosis
- Serum creatinine ≥ 221 μmol/L or CKD-EPI eGFR < 25 mL/min not
related to cardiac condition or the need for chronic renal
replacement therapy
- Psychiatric disease/disorder, irreversible cognitive dysfunction, or
psychosocial issues that are likely to impair compliance with the
study protocol and LVAD management
CKD-EPI, Chronic Kidney Disease–Epidemiology Collaboration;
eGFR, estimated glomerular ﬁltration rate; INTERMACS, Inter-
agency Registry for Mechanically Assisted Circulatory Support;
LVAD, left ventricular assist device; PAP, pulmonary artery pressure.
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Study overview: CardioMEMS allocation and
patient ﬂow
The study can be divided into three phases (A–C), as is shown
in Figure 1. The different phases are described below.
Phase A: Pre-left ventricular assist device optimization phase
(1 week)
Every consecutive patient, who is accepted by the heart team
for scheduled LVAD implantation (both destination therapy
and bridge to transplant), is screened for eligibility to partici-
pate in the HEMO-VAD study. After the heart team decision
has been taken to plan an LVAD implantation, the
CardioMEMS sensor is implanted as soon as possible, that
is, at 0–1 day. LVAD implantation is to be scheduled with
the aim within 1 week in semi-elective to elective patients,
with minimum 1 day and maximum within 4 weeks after
heart team consensus.
After enrolment and informed consent, but prior to HM-3
implantation, subjects will be implanted with the
CardioMEMS HF system. The baseline visit (t = 0) includes
the day of the right heart catheterization (Swan–Ganz) occur-
ring in all patients and the implantation of the CardioMEMS
PA sensor in the left lower lobe PA. PAP data will be utilized
to guide adjustments of medical therapy (e.g. diuretics, vaso-
dilators, and inotropes or phosphodiesterase inhibitors) for
optimization of the haemodynamic status prior to HM-3 im-
plantation, with the aim to improve the pre-LVAD
INTERMACS class, which is one of the best parameters of
outcome. The main objective is to ensure optimal status to
decompress venous congestion (unloading) of the RV and
mean PAP (mPAP) below 25 mmHg. Recommendations for
these adjustments will be provided with options for the
physician as deemed clinically appropriate.
In this PAP-guided phase prior to LVAD implantation, the
physician will use the PAP obtained by the sensor to optimize
the patient condition and ﬂuid status proceeding towards
LVAD surgery. This contains optimal ﬂuid status (euvolemia)
and lowered right heart pressures (unloading the RV) to opti-
mal capacity as judged by the treating clinician, laboratory
values, and echocardiographic parameters. The clinician
normally uses a treatment course of phosphodiesterase
inhibitors or inotropes and titrates diuretics, angiotensin-
converting enzyme inhibitors, and nitrates dosages. Another
aspect of the pre-LVAD optimization phase is to learn more





• Improve patient selection pre-LVAD
implantation
• Evaluate timing of LVAD implantation
• Optimizing clinical patient status
towards surgery




Guide post-cardiac surgery treatment









Guide LVAD therapy remotely
Evaluate further improvement of
PA-guided LVAD pump settings
Decrease the high rate of HF-related
hospitalizations (70% ﬁrst year)
Early discovery of late complications
of LVAD
Evaluate pulmonary hypertension on
LVAD therapy
HF, heart failure; INTERMACS, Interagency Registry for Mechani-
cally Assisted Circulatory; LVAD, left ventricular assist device; PA,
pulmonary artery; RV; right ventricle.
Table 4 Study endpoints
Primary end points
- Safety of the hybrid construction of CardioMEMS and LVAD
- Feasibility of the hybrid construction of CardioMEMS and LVAD
- Clinical endpoints deﬁned as
• Number of HF-related hospitalizations
• Number of LVAD related complications (such as tamponade,
RV failure, GI bleeding, infection, pump thrombosis, and
haemolysis)
Secondary endpoints
- The number of improvements in INTERMACS classes during
pre-operative optimization phase
- Time to reach optimal condition for surgery in the pre-operative
phase (days)
- PredictivevalueofPAPduring follow-up inoutpatient clinic LVAD
patients of risk of RV failure, GI bleeding, suboptimal ﬂuid
balance, anddevelopment of long-termaortic valve insufﬁciency
- Monitoring of PAP and pulmonary hypertension and
reversibility of pulmonary hypertension in LVAD patients
- Detection of arrhythmia and heart rate monitoring with
CardioMEMS in LVAD
- Feasibility of pump optimization using CardioMEMS during
rpm test and number of pump changes
- Changes in quality of life (KCCQ, EQ-5D-5L, and PHQ-9)
- 6MHWD post-HM-3 implantation and changes during
outpatient clinic phase
- HF medication changes (counts and TDD) during pre-LVAD
implantation phase, post-LVAD implantation phase, and
outpatient clinical phase
- Iron deﬁciency before and after LVAD treatment, incidence of
GI bleeding, and the relationship with PAP and early discovery
of occult blood loss
- Change in renal function in relation to PAP and diuretic
medication dosage
- LDH, PAP, and the incidence of pump thrombosis and
haemolysis in LVAD patients
- Number of days hospitalized, number of days requiring
inotropic support, and number of physical contact in the
outpatient clinic
- Percentage of days PAP in goal range, changes in PAP from
baseline, and analysis of PAP waveforms in LVAD
GI, gastrointestinal; HF, heart failure; HM-3; Heart Mate 3;
INTERMACS, Interagency Registry for Mechanically Assisted Circula-
tory Support; KCCQ, Kansas City Cardiomyopathy Questionnaire;
LDH, lactate dehydrogenase; LVAD, left ventricle assist device;
PAP, pulmonary artery pressure; PHQ-9, Patient Health Question-
naire 9; rpm, rotations per minute; RV, right ventricle; TDD, total
daily dose; 6MHWD, 6 min hall walk distance.
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on optimal timing window of LVAD surgery. When optimal
timing window to proceed to LVAD surgery is reached, the
HM-3 implantation follows. Based on clinical judgement or
clinical urgency, this timing can be adjusted.
Phase B: Clinical phase
After LVAD implantation, the patients will be admitted to the
intensive care unit (ICU), where patients will receive regular
care. At the ICU, potential interference between the
implanted PAP sensor, LVAD controller, and potential other
equipment will be tested, as an important part of the feasibil-
ity and safety of this novel hybrid construction. In addition to
the regular care, daily pressure readings provided by the
CardioMEMS system will be used to guide HF treatment,
according to the predeﬁned goals: diastolic PAP will be
targeted and maintained between 8 and 15 mmHg as well as
mPAP below 25mmHg. Furthermore, PAP changes might indi-
cate the presence of complications such as RV failure,
infection, or cardiac tamponade, on top of echocardiography
in an earlier stage. At the moment, haemodynamic recordings
after LVAD implantation are very limited in the current litera-
ture to provide insights in these mechanisms. Recently, a
retrospective sub-analysis of the CHAMPION trial provided
some information of PAP changes after LVAD implantation,
suggesting that additional haemodynamic information has
the potential to improve LVAD management.16 However,
information during the hospitalization for LVAD implantation
and during potential LVAD-related complications is still lacking.
When clinically stable, patients will be transferred to the
HF department. Patients will receive the usual care, and at
least once a day, pressure readings will be continued.
Haemodynamic feedback will be used for optimizing HF
medication titration, leading to tailored therapy (maintain
normal PAP), and evaluating haemodynamic changes during
potential complications. During admission, LVAD care echo-
cardiography will be performed to optimize pump settings
(rpm testing), as is standard care, only with additional
pressure feedback for the CardioMEMS system, which will
be analysed separately. Furthermore, patients will be trained
in using the LVAD device, controller, and exchange batteries
as well as operating the home monitoring unit and instructed
to take daily PAP measurements.
Phase C: Outpatient monitoring phase (long-term follow-up)
Throughout the long-term follow-up period and subsequent
hospitalizations, the pressure data upload will be performed
at least daily using the home monitoring system and the
Merlin.net website. Pressures will be reviewed remotely at
least once a week and more frequently when pressures are
outside the target range, on the Merlin.net website, with
anticipation of treatment alterations based on maintaining
normal PAP. Patients will be followed during regular outpa-
tient clinic visits, approximately at 1, 2, and 4 weeks and 3,
6, 9, and 12 months. During these visits, patients will receive
standard care, expanded with speciﬁc blood, urinary, and
echocardiography parameters, as well as questionnaires on
quality of life, and the performance status will be assessed.
Parameters of interest
Primary study parameter(s) of CardioMEMS device
Daily PAP measurements will be performed in the preopera-
tive period towards LVAD implantation, direct post-operative
period on ICU, clinical department, and the regular
outpatient clinic setting. Measurements record systolic PAP,
diastolic PAP, mPAP, mean trend, and heart rate.
Our study protocol will further study PAP in relation to the
following:
• serial lactate dehydrogenase levels, international normal-
ized ratio values, and pump thrombosis;
• serial creatinine clearance, urinary samples, and kidney
dysfunction;
• serial iron status and gastrointestinal bleeding incidence;
and
• serial measurements of quality of life at 3, 6, and
12 months.
Other parameters of interest
Baseline Swan–Ganz measurements (including cardiac index,
systolic PAP, diastolic PAP, mPAP, wedge pressures, RV pres-
sures, right atrial pressures, and PA pulsatility index) are
Figure 1 Study overview. LVAD, left ventricular assist device.
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recorded at baseline during CardioMEMS implantation (pro-
tocol describing the Swan–Ganz procedure and CardioMEMS
implantation is described in detail in Table 5). Vasoreactivity
is tested during the LVAD screening, using continuous admin-
istration of an i.v. vasodilating agent, such as nitroglycerin, in
increased dosage. During the entire study, at regular inter-
vals, clinical parameters (such as heart rate, blood pressure,
weight, and symptoms of congestion), laboratory results
(including standard routine care laboratory results, renal
function, haemolysis parameters, iron status, and bio-
markers), urine analysis (proteinuria), LVAD parameters log
ﬁle (rpm, ﬂow, pulse index, power, pulsatility index events,
and suction events), echocardiography parameters (such as
ventricle dimensions, valve patency, ventricle and vena cava
dimensions, tricuspid annular plane systolic excursion, and
rpm measurements), electrocardiogram, performance status
(New York Heart Association and INTERMACS classiﬁcation,
and 6 min hall walk test), and quality of life questionnaires
(EQ-5D-5L, Kansas City Cardiomyopathy Questionnaire, and
Patient Health Questionnaire 9) will be assessed.
Device description and implantation procedure
The device description and implantation procedure of the
CardioMEMS HF sensor system (Abbott Inc., Atlanta, GA,
USA)17 and of the HM-3 LVAD (Abbott Inc., Pleasanton, CA,
USA) have been published previously.18
Statistical analysis
For the purpose of this study, all data will be recorded on a
case report form and introduced into the study database
environment. All patient data will be collected by a dedicated
research fellow or PhD student. Baseline quantitative data
will be presented with mean ± standard deviation or median
with interquartile range when appropriate. In general, statis-
tical analyses in this pilot study will be descriptive in nature.
The data will be summarized using descriptive statistics (e.g.
N, mean, standard deviation, median, minimum, and maxi-
mum) or frequency (e.g. N, %) as appropriate. Changes in
PAP will be measured as area under the curve of PAP relative
to the baseline. Changes in quality of life (assessed using
EQ-5D-5L, Kansas City Cardiomyopathy Questionnaire, and
Patient Health Questionnaire 9) will be analysed. The primary
time point for safety analyses is 6 months post-enrolment.
The time point for analyses of feasibility and haemodynamic
performance is at 6 and 12 months post-enrolment.
Discussion
The HEMO-VAD pilot study is the ﬁrst prospective study
investigating haemodynamic guided management of HM-3
LVAD patients with an implantable pressure sensor
(CardioMEMS). The primary goal is to assess the safety and
feasibility of this hybrid construction and evaluate its additive
value in optimizing treatment in LVAD patients. Reaching and
maintaining optimal ﬂuid status and maximizing optimal
medical treatment and timing of surgery towards LVAD
therapy (preoperative and post-operative stages) are the
main focus. Additionally, this study will evaluate the use of
frequent remote measurement of PAP to discover early and
late complications of LVAD therapy during hospitalization.
Finally, we evaluate whether direct haemodynamic feedback
can inﬂuence outpatient clinical management and optimize
pump settings on top of current standard care.
Left ventricular assist device therapy is a complex entity
with high risk of mortality and morbidity without clear
tools to predict outcome or complications during treat-
ment.9,19–23 From a haemodynamic point of view, RV failure
is the most common serious complication after LVAD implan-
tation. RV failure after LVAD implantation can be divided into
early or late RV failure (<4 weeks and>4 weeks after implan-
tation, respectively). Early RV failure occurs in as much as
20–40%5,9 and late RV failure in 15% of LVAD patients.11
Preoperative assessment of RV function is essential in LVAD
screening but dependent on ﬁlling status and right heart pres-
sures. Prolonged elevated PAP is a major cause of RV failure,
Table 5 Swan–Ganz and CardioMEMS implantation protocol
1 Insert, using ultrasound guidance, a 7F balloon-tipped Swan–Ganz
pulmonary artery catheter through the femoral vein.
2. Obtain standard Swan–Ganz right heart catheterization pressure
reading at RA, RV, PA, and pulmonary capillary wedge pressure.
Preferably right pulmonary artery.
3. Obtain the cardiac output using thermodilution (using 10 mL NaCl
0.9% per measurement), calculated as the average of at least three
adequate measurements.
4. Introduce the adequate pigtail shaped into the venous sheath and
localize the pigtail with ﬂuoroscopy into the left lower pulmonary
artery. And perform a standard pulmonary artery angiogram of the
left lower pulmonary artery.
5. Perform standard measurements of vessel size and reassure
maximum vessel size diameter and anatomical requirements (inner
vessel diameter must be >7 mm) suited for CardioMEMS.
6. Insert the CardioMEMS catheter in the left lower pulmonary artery
targeted vessel site and conﬁrm adequate positioning by ﬂuoroscopy
7. Turn the catheter switch button to release the wires of the
CardioMEMS sensor, which ﬁxes itself in the pulmonary artery.
Conﬁrm adequate positioning of the device by the radiopaque
markers with ﬂuoroscopy
8. Reintroduce the Swan–Ganz catheter and position the catheter in the
right pulmonary artery. Start calibrating and equilibrate the
CardioMEMS pressure readings with the simultaneous Swan–Ganz
pressure readings (nulling of the sensor). Perform baseline
measurements and calibration three times and conﬁrm
measurements and baseline recordings are identical.
9. Remove Swan–Ganz catheter. Remove the venous sheath from the
femoral vein. At preference of the operator, use a closure device
for the femoral vein, manual compression, or pressure bandage at
the venous puncture site.
PA, pulmonary artery; RA, right atrium; RV, right ventricle.
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but pulmonary hypertension alone is not a contraindication for
LVAD implantation, unless there is already severe RV failure
pre-LVAD. One of the caveats is that RV failure after LVAD im-
plantation is highly unpredictable.5,12 Current risk assessment
scores have limited predictive value and clinical usefulness for
predicting LVAD-related complications, especially RV fail-
ure.9,10,24 Recently, the EUROMACS-RHF risk score has been
developed and aims to predict early RV failure and associated
mortality after LVAD implantation.10 At the moment, the best
predictive variable for RV failure post-LVAD implantation is RV
function prior to surgery as assessed by echocardiography,
which largely depends on ﬂuid status, vascular resistance,
degree to which pulmonary pressures are elevated, and
severity of tricuspid valve regurgitation. Echocardiography
can be used to evaluate RV function but correlated poorly with
the development of RV failure. Right heart catheterization is
the gold standard to assess RV workload and function;
however, this is an invasive procedure, performed at one
moment in time, and greatly depends on loading conditions
at that moment. More tools are needed to adequately predict
and assess the risk of post-LVAD RV failure.
We hypothesize that PAP is key in the preoperative stage to
deliver the patient to the surgeon in optimal decongested
state to lower the impact of the surgery on the RV. After
implantation, we hypothesize that PAP can be used as a
marker of treatment success of left ventricular (LV) unloading
by the LVADwith insight into residual ﬁxed vascular resistance,
which may be a target for therapies with the goal of protecting
RV function by reducing afterload. Additionally, PAP informa-
tion may predict potential complications of LVADs such as oc-
cult bleeding, haemolysis, or pump thrombosis in association
with the ﬁxed measurement from the pump. Better prediction
of upcoming RV dysfunction, directed by measuring PAP com-
bined with optimization of therapy based on haemodynamic
feedback, might lead to a better LV unloading, lowering the
PAP and lowering chances of RV failure.
As described previously, pulmonary hypertension alone is
not a contraindication for LVAD implantation. Often PAP and
pulmonary vascular resistance normalize several months after
LVAD implantation, which cannot be matched by any medical
therapy. Furthermore, LVAD implantation appears to be the
best tool for reversal of ‘ﬁxed’ pulmonary hypertension.12
However, continuous data of PAP after LVAD implantation
are not available at this moment. This study will provide novel
insights of changes in PAP data during LVAD therapy.
Despite existing risk scores,21,25–27 an adequate measuring
tool for determining the ideal LVAD implantation timing is still
missing. Multiple studies13,21,26,27 demonstrated that sicker
and more instable patients, indicated by a lower INTERMACS
proﬁle, had worse survival outcome than less sick patients,
indicated by a higher INTERMACS proﬁle.
It has been shown that an improvement in risk score
shortly before LVAD implantation lead to a better outcome
after LVAD implantation.25 We hypothesize that the
haemodynamic feedback, provided by the implantable hae-
modynamic monitoring, will lead to a tailor made, optimized
medical therapy pre-LVAD. By doing so, we think that the
patient will get in an optimal clinical condition, potentially
rising the INTERMACS class from 2 to 3, or 3 to 4. Further-
more, we hypothesize that haemodynamic feedback provides
additional information in order to determine the optimal
timing of LVAD implantation. We hypothesize that optimizing
the patients’ clinical condition and the timing of LVAD implan-
tation will lead to a better clinical outcome.
Other research areas of interest
Pulmonary artery pressure data provided by the CardioMEMS
during LVAD therapy provide a unique opportunity of a
wealth of novel haemodynamic data.
In the post-operative period, one of the major complica-
tions of LVAD is bleeding (40%) or tamponade requiring
surgical intervention (20%).20,22 The clinical diagnosis of
tamponade is often missed in this complex patient group,
as the pump keeps on providing ﬂow even in the late stages
of tamponade.20 In case of tamponade, we expect to detect a
decrease in PAP if the pericardial ﬂuid impairs the ﬁlling of
the right side of the heart; at the left side, located pockets
could also impair pump function and increase PAP.
CardioMEMS might be a valuable tool to detect the changes
in a much earlier stage. In contrary, a major post-operative
bleeding might lead to a drop in PAP due to loss of circulating
volume. Additionally, in the outpatient clinical phase, the
haemodynamic data could provide important feedback on
development of frequent complications such as gastrointesti-
nal bleeding (20–40%),19,28 pump thrombosis (8–10%),23 or
renal dysfunction (12%)21 at an earlier stage.
As described previously,29 ﬁlling pressures will rise as a re-
sult of congestion. Congestion can be a sign of development
of aortic valve regurgitation and pump dysfunction (kinking
outﬂow graft or bent relief), resulting in higher PAP. For
example pump thrombosis leads to LVAD dysfunction and
impaired LV unloading. This will lead to signs and symptoms
of HF and pulmonary congestion.23,30
Additionally, considering renal function,8 lowering PAP by
better unloading LV and providing better cardiac output will
improve renal function. However, when kidney failure occurs
and patients’ urine production declines, PAP might rise. We
will study these issues with separate research subthemes
within the HEMO-VAD pilot study.
Limitations
The design of our study has some limitations. Due to the pilot
study design we include only a small number of patients, with
the aim to test the feasibility of this hybrid construction. Also,
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we have not included a control group in the study design, be-
cause of the observational nature. Still, the current study is
the ﬁrst prospective study investigating this new hybrid com-
bination of CardioMEMS with an LVAD providing a wealth of
novel haemodynamic data. After feasibility is demonstrated,
we need to test the clinical value of this concept in a large-
scale randomized clinical trial in patients scheduled for LVAD
therapy as is currently anticipated.
Conclusions
The HEMO-VAD study will test the safety and feasibility of
the hybrid construction of PAP measurements by the
CardioMEMS device and LVAD therapy during 6 and
12 months of follow-up.
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